trending Market Intelligence /marketintelligence/en/news-insights/trending/BhoW4MGdPgZEV1CQ90gBTQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Roche books 13% rise in Q3 sales, raises 2019 sales outlook

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Roche books 13% rise in Q3 sales, raises 2019 sales outlook

Roche Holding AG said its third-quarter sales grew 13% year over year and raised its outlook for the full year.

The Basel, Switzerland-based pharmaceutical and diagnostics company's group sales reached about CHF15.60 billion for the third quarter, up from CHF13.97 billion in the year-ago period.

The S&P Global Market Intelligence consensus third-quarter revenue estimate is about CHF15.08 billion.

Third-quarter sales from the company's pharmaceuticals division reached CHF12.37 billion, up 15% year over year from CHF10.86 billion. Roche's diagnostics division also saw a 6% year over year growth in sales to CHF3.23 billion.

For the nine months ended September, sales reached CHF46.07 billion, up 10% at constant exchange rates from CHF42.08 billion a year ago.

Multiple sclerosis drug Ocrevus, hemophilia therapy Hemlibra and cancer drugs Tecentriq, Perjeta and Avastin were key growth drivers for the first three quarters of 2019.

The company raised its full-year 2019 sales outlook and now expects full-year sales to grow in the high single digit range at constant exchange rates compared to a previous expectation of growth in the mid- to high single-digit range at constant exchange rates.

Core EPS is still expected to grow broadly in line with sales at constant exchange rates and the company expects to further increase its dividend in Swiss francs.